Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0094)
Name
Deferiprone
Synonyms
deferiprone; 30652-11-0; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; Ferriprox; 3-hydroxy-1,2-dimethylpyridin-4(1H)-one; CP20; 1,2-dimethyl-3-hydroxy-4-pyridone; 1,2-Dimethyl-3-hydroxypyrid-4-one; APO-66; 3-hydroxy-1,2-dimethylpyridin-4-one; 1,2-Dimethyl-3-hydroxypyridine-4-one; 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-; APO-066; DN-180-01-AF; Deferipron; MFCD00134497; Deferiprone (INN); PL-1; L1; CHEBI:68554; 1,2-Dimethyl-3-hydroxy-4(1H)-pyridinone; CP-20; DN-18001AF; NSC-758880; 2BTY8KH53L; MLS000069481; HK-1; PL1; DTXSID6040666; 4(1H)-Pyridinone, 1,2-dimethyl-3-hydroxy-; SMR000059136; DEFERIPRONE [INN]; L-1; CP20 (Chelating agent); Ferriprox (TN); UNII-2BTY8KH53L; BRN 1447108; Deferidone; Deferiprona; Deferum; Deferiprone [USAN:INN:BAN]; CCRIS 8318; 1,2-dimethyl-3-hydroxy-4-pyridinone; 3-Hydroxy-1,2-dimethyl-4-pyridinone; Opera_ID_366; 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone; DEFERIPRONE [MI]; 4(1H)-Pyridone, 3-hydroxy-1,2-dimethyl-; Deferiprone (USAN/INN); DEFERIPRONE [USAN]; DEFERIPRONE [VANDF]; DEFERIPRONE [MART.]; SCHEMBL94474; DEFERIPRONE [WHO-DD]; MLS000758227; MLS001424029; MLS006011689; CHEMBL70927; DEFERIPRONE [EMA EPAR]; CRMD-001; GTPL7456; DTXCID4020666; HSDB 8335; TZXKOCQBRNJULO-UHFFFAOYSA-; DEFERIPRONE [ORANGE BOOK]; EX-A972; TZXKOCQBRNJULO-UHFFFAOYSA-N; CP020; DEFERIPRONE [EP MONOGRAPH]; HMS2051C05; HMS2232E24; HMS3264P17; HMS3393C05; HMS3873L13; Pharmakon1600-01504512; BCP09606; HY-B0568; 3-hydroxy-1,2-dimethylpyrid-4-one; Tox21_112429; BBL036482; BDBM50525976; CGP-37391; NSC758880; s4067; STL559018; 1,2-dimetyl-3-hydroxy-4-pyridinone; AKOS015902286; CCG-100760; CS-5240; DB08826; DS-5493; NC00010; NSC 758880; 3-hydroxy-1,2-dimethyl-4- pyridinone; 3-hydroxy-1,2-dimethyl-pyridin-4-one; NCGC00090548-01; NCGC00090548-02; NCGC00090548-04; NCGC00090548-05; AC-33026; BP-12415; SY052576; SBI-0207041.P001; CAS-30652-11-0; FT-0606424; H0944; D07416; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 98%; AB00572605_11; AB00572605_12; EN300-1718313; 3-hydroxy-1,2-dimethyl-1,4-dihydropyridin-4-one; A820470; Q749664; SR-01000721891; Deferiprone 1,2-DIMETHYL-3-HYDROXY-4-PYRIDONE; SR-01000721891-4; Z1255390865; InChI=1/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C7H9NO2
IUPAC Name
3-hydroxy-1,2-dimethylpyridin-4-one
Canonical SMILES
CC1=C(C(=O)C=CN1C)O
InChI
InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
InChIKey
TZXKOCQBRNJULO-UHFFFAOYSA-N
PubChem CID
2972
TTD Drug ID
D0N0OU
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Nervous system disease ICD-11: 8E7Z
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model rHNs (Rat hippocampal neuronal cells)
In Vivo Model
Sprague-Dawley rat pups at postnatal day (PND) 6 and 15-month-old male C57BL/6 mice were used in the present study. For ketamine GA, rat pups at PND 6 or 15-month-old mice received ketamine (75 mg/kg) intraperitoneally daily for three consecutive days. For sevoflurane GA, animals were put in an anaesthetizing chamber delivered with 3% sevoflurane plus 30% oxygen (O2) for 2 h daily for three consecutive days. For control experiments, 30% O2 was delivered at the same flow rate. For drug treatment, DFP (75 mg/kg, intraperitoneally, synthesized in China Peptides Co., Ltd., Shanghai, China) or DMT1i (50 mg/kg, orally, MedChemExpress, China) was administered to the animals 1 h before GA daily for three consecutive days.

    Click to Show/Hide
Response regulation Iron is essential for normal neuronal function, and excess iron in the brain is implicated in several neurodegenerative diseases. Chelating neurotoxic iron with deferiprone ameliorated general anaesthesia (GA)-induced cognitive deficits and suggest that iron restriction might provide a preventative effect for paediatric patients undertaking GA.
References
Ref 1 Iron overload contributes to general anaesthesia-induced neurotoxicity and cognitive deficits. J Neuroinflammation. 2020 Apr 11;17(1):110. doi: 10.1186/s12974-020-01777-6.